Hoth Therapeutics (NASDAQ:HOTH) Posts Quarterly Earnings Results

Hoth Therapeutics (NASDAQ:HOTH) announced its earnings results on Wednesday. The company reported ($0.30) earnings per share for the quarter, Zacks reports.

Hoth Therapeutics Stock Performance

Shares of Hoth Therapeutics stock remained flat at $1.28 during trading on Wednesday. The stock had a trading volume of 139,473 shares, compared to its average volume of 3,255,705. Hoth Therapeutics has a 12 month low of $0.66 and a 12 month high of $3.80. The company has a fifty day simple moving average of $1.53 and a 200-day simple moving average of $1.29. The stock has a market cap of $16.97 million, a P/E ratio of -1.20 and a beta of 0.63.

Institutional Trading of Hoth Therapeutics

An institutional investor recently raised its position in Hoth Therapeutics stock. Geode Capital Management LLC boosted its holdings in Hoth Therapeutics, Inc. (NASDAQ:HOTH) by 8.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 122,575 shares of the company’s stock after buying an additional 9,071 shares during the quarter. Geode Capital Management LLC owned approximately 0.93% of Hoth Therapeutics worth $143,000 at the end of the most recent reporting period. 7.08% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Wall Street Zen lowered Hoth Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. D. Boral Capital reissued a “buy” rating and issued a $5.00 target price on shares of Hoth Therapeutics in a research report on Monday, August 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Hoth Therapeutics in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Hoth Therapeutics has an average rating of “Hold” and a consensus price target of $4.50.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.